Robert J. Myerson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Robert J. Myerson has a total of 134 co-authors. Here are the top co-authors by number of shared publications:
- Eduardo Gerardo Moros
Department of Radiation Oncology Moffitt Cancer Center Tampa Florida USA
3 shared publications Albert Chang
University of California San Francisco, San Francisco, CA
2 shared publicationsElisa H. Birnbaum
2 shared publicationsIra J. Kodner
2 shared publications- James W. Fleshman
Washington University School of Medicine, Department of Surgery, Section of Colon and Rectal Surgery, St Louis, Missouri
2 shared publications Joel Picus
2 shared publications
Latest Publications
- 7 December 2016
- Published by Taylor & Francis in International Journal of Hyperthermia
- Vol. 33 (3) , 364-365
Incorporating detailed biology in hyperthermia treatment planning: a necessary condition for progress
(2017). Incorporating detailed biology in hyperthermia treatment planning: a necessary condition for progress. International Journal of Hyperthermia: Vol. 33, No. 3, pp. 364-365.
- 7 December 2016
- Published by Taylor & Francis in International Journal of Hyperthermia
- Vol. 33 (3) , 364-365
Incorporating detailed biology in hyperthermia treatment planning: a necessary condition for progress
(2017). Incorporating detailed biology in hyperthermia treatment planning: a necessary condition for progress. International Journal of Hyperthermia: Vol. 33, No. 3, pp. 364-365.
- 20 January 2014
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 32 (3) , 460
Predictors of radiotherapy-related gastrointestinal toxicity from anal cancer DP-IMRT: Secondary analysis of RTOG 0529.
460 Background: Radiation Therapy Oncology Group (RTOG) 0529 assessed feasibility of dose-painted intensity-modulated radiation therapy (DP-IMRT) to reduce the acute morbidity of chemoradiation with 5-fluorouracil (5FU) and mitomycin-C (MMC) for T2-4N0-3M0 anal cancer. This secondary analysis was performed to identify patient (pt) and treatment factors associated with acute and late gastrointestinal (GI) adverse events (AEs). Methods: RTOG 0529 treatment plans were reviewed to extract dose-volume data for tightly contoured small bowel (SB), loosely contoured anterior pelvic contents (APC), and uninvolved portions of colon outside the clinical target volume (UC). T-tests were performed to evaluate differences in the mean absolute volumes of each critical structure receiving doses ≥ 5 to 60 Gy (V5-V60) in 5 Gy increments between pts with and without ≥ grade (G) 2, acute and late GI AEs, and ≥G3 acute GI AEs using the NCI Common Terminology Criteria, version 3. Acute is defined as ≤ 90 days from the start of treatment and late is > 90 days. Additional factors (age, location, gender, race, Zubrod, grade, size, stage, prone vs supine position) were also evaluated in multivariate (MV) logistic regression (acute AEs) or Cox proportional hazards models (late AEs) to evaluate correlation with GI AEs. Results: Among 52 evaluable pts, ≥G2 acute, ≥G2 late, and ≥G3 acute GI AEs were observed in 35, 17, and 10 pts, respectively. Trends (p4cm, and worse Zubrod. SB and APC dose parameters remained correlated with GI AEs on MV analysis. Treatment in the prone vs supine position correlated with lower SB V10-V35 and APC V5-V20, although no significant differences in GI AEs were observed. Conclusions: Acute and late GI AEs from 5FU/MMC chemoradiation using DP-IMRT correlates with RT dose to the SB and APC. Further analysis is underway to determine critical structure cut-point parameters that may aid treatment plan optimization for anal cancer DP-IMRT. Supported by RTOG U10 CA21661, CCOP U10 CA3742 and ATC U24 CA 81647 NCI grants. Clinical trial information: NCT00423293.
- 20 January 2014
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 32 (3) , 460
Predictors of radiotherapy-related gastrointestinal toxicity from anal cancer DP-IMRT: Secondary analysis of RTOG 0529.
460 Background: Radiation Therapy Oncology Group (RTOG) 0529 assessed feasibility of dose-painted intensity-modulated radiation therapy (DP-IMRT) to reduce the acute morbidity of chemoradiation with 5-fluorouracil (5FU) and mitomycin-C (MMC) for T2-4N0-3M0 anal cancer. This secondary analysis was performed to identify patient (pt) and treatment factors associated with acute and late gastrointestinal (GI) adverse events (AEs). Methods: RTOG 0529 treatment plans were reviewed to extract dose-volume data for tightly contoured small bowel (SB), loosely contoured anterior pelvic contents (APC), and uninvolved portions of colon outside the clinical target volume (UC). T-tests were performed to evaluate differences in the mean absolute volumes of each critical structure receiving doses ≥ 5 to 60 Gy (V5-V60) in 5 Gy increments between pts with and without ≥ grade (G) 2, acute and late GI AEs, and ≥G3 acute GI AEs using the NCI Common Terminology Criteria, version 3. Acute is defined as ≤ 90 days from the start of treatment and late is > 90 days. Additional factors (age, location, gender, race, Zubrod, grade, size, stage, prone vs supine position) were also evaluated in multivariate (MV) logistic regression (acute AEs) or Cox proportional hazards models (late AEs) to evaluate correlation with GI AEs. Results: Among 52 evaluable pts, ≥G2 acute, ≥G2 late, and ≥G3 acute GI AEs were observed in 35, 17, and 10 pts, respectively. Trends (p4cm, and worse Zubrod. SB and APC dose parameters remained correlated with GI AEs on MV analysis. Treatment in the prone vs supine position correlated with lower SB V10-V35 and APC V5-V20, although no significant differences in GI AEs were observed. Conclusions: Acute and late GI AEs from 5FU/MMC chemoradiation using DP-IMRT correlates with RT dose to the SB and APC. Further analysis is underway to determine critical structure cut-point parameters that may aid treatment plan optimization for anal cancer DP-IMRT. Supported by RTOG U10 CA21661, CCOP U10 CA3742 and ATC U24 CA 81647 NCI grants. Clinical trial information: NCT00423293.
- 18 December 2013
- Published by Taylor & Francis in International Journal of Hyperthermia
- Vol. 30 (1) , 1-5
Components of a hyperthermia clinic: Recommendations for staffing, equipment, and treatment monitoring
Like other technically sophisticated medical endeavours, a hyperthermia clinic relies on skilled staffing. Physicians, physicists and technologists perform multiple tasks to ensure properly functioning equipment, appropriate patient selection, and to plan and administer this treatment. This paper reviews the competencies and tasks that are used in a hyperthermia clinic.
- 18 December 2013
- Published by Taylor & Francis in International Journal of Hyperthermia
- Vol. 30 (1) , 1-5
Components of a hyperthermia clinic: Recommendations for staffing, equipment, and treatment monitoring
Like other technically sophisticated medical endeavours, a hyperthermia clinic relies on skilled staffing. Physicians, physicists and technologists perform multiple tasks to ensure properly functioning equipment, appropriate patient selection, and to plan and administer this treatment. This paper reviews the competencies and tasks that are used in a hyperthermia clinic.
- 1 October 2013
- Vol. 33 (10) , 4557-66
Postoperative 5-FU based radiochemotherapy in rectal cancer: retrospective long term results and prognostic factors of a pooled analysis on 1,338 patients.
To evaluate survival outcomes of patients in pStage II-III rectal cancer treated with adjuvant 5-fluorouracil-based radiochemotherapy and to retrospectively analyze the impact of prognostic variables on local control, metastasis-free survival and cause-specific survival. A total of 1,338 patients, treated between 1985-2005 for locally advanced rectal cancer, who underwent surgery and postoperative 5-fluorouracil-based chemoradiation, were selected. The actuarial 5- and 10-year outcomes were: local control 87.0%-84.1%, disease-free survival 61.6%-52.1%, metastasis-free survival 72.0%-67.2%, cause-specific survival 70.4%-57.5%, and overall survival 63.8%-53.4%. Better outcomes were observed in patients with IIA, IIIA stage. Multivariate analyses showed that variables significantly affecting metastasis-free survival were pT4 and pN2, while for cancer-specific survival those variables were age >65 years, pT4, pN1, pN2, distal tumors and number of lymph nodes removed ≤ 12. This study confirmed that among stage II-III rectal cancer patients there are subgroups of patients with different clinical outcomes.
- 1 October 2013
- Vol. 33 (10) , 4557-66
Postoperative 5-FU based radiochemotherapy in rectal cancer: retrospective long term results and prognostic factors of a pooled analysis on 1,338 patients.
To evaluate survival outcomes of patients in pStage II-III rectal cancer treated with adjuvant 5-fluorouracil-based radiochemotherapy and to retrospectively analyze the impact of prognostic variables on local control, metastasis-free survival and cause-specific survival. A total of 1,338 patients, treated between 1985-2005 for locally advanced rectal cancer, who underwent surgery and postoperative 5-fluorouracil-based chemoradiation, were selected. The actuarial 5- and 10-year outcomes were: local control 87.0%-84.1%, disease-free survival 61.6%-52.1%, metastasis-free survival 72.0%-67.2%, cause-specific survival 70.4%-57.5%, and overall survival 63.8%-53.4%. Better outcomes were observed in patients with IIA, IIIA stage. Multivariate analyses showed that variables significantly affecting metastasis-free survival were pT4 and pN2, while for cancer-specific survival those variables were age >65 years, pT4, pN1, pN2, distal tumors and number of lymph nodes removed ≤ 12. This study confirmed that among stage II-III rectal cancer patients there are subgroups of patients with different clinical outcomes.
- 22 October 2012
- Published by Wiley in Medical Physics
- Vol. 39 (11) , 6838-6846
Design and dosimetric characteristics of a new endocavitary contact radiotherapy system using an electronic brachytherapy source
Purpose: To present design aspects and acceptance tests performed for clinical implementation of electronic brachytherapytreatment of early stage rectal adenocarcinoma. A dosimetric comparison is made between the historically used Philips RT-50 unit and the newly developed Axxent® Model S700 electronic brachytherapysource manufactured by Xoft (iCad, Inc.). Methods: Two proctoscope cones were manufactured by ElectroSurgical Instruments (ESI). Two custom surface applicators were manufactured by Xoft and were designed to fit and interlock with the proctoscope cones from ESI. Dose rates, half value layers (HVL), and percentage depth dose (PDD) measurements were made with the Xoft system and compared to historical RT-50 data. A description of the patient treatment approach and exposure rates during the procedure is also provided. Results: The electronic brachytherapy system has a lower surfacedose rate than the RT-50. The dose rate to water on the surface from the Xoft system is approximately 2.1 Gy/min while the RT-50 is 10–12 Gy/min. However, treatment times with Xoft are still reasonable. The HVLs and PDDs between the two systems were comparable resulting in similar doses to the target and to regions beyond the target. The exposure rate levels around a patient treatment were acceptable. The standard uncertainty in the dose rate to water on the surface is approximately ±5.2%. Conclusions: The Philips RT-50 unit is an out-of-date radiotherapy machine that is no longer manufactured with limited replacement parts. The use of a custom-designed proctoscope and Xoft surface applicators allows delivery of a well-established treatment with the ease of a modern radiotherapy device. While the dose rate is lower with the use of Xoft, the treatment times are still reasonable. Additionally, personnel may stand farther away from the Xoft radiationsource, thus potentially reducing radiation exposure to the operator and other personnel.
- 22 October 2012
- Published by Wiley in Medical Physics
- Vol. 39 (11) , 6838-6846
Design and dosimetric characteristics of a new endocavitary contact radiotherapy system using an electronic brachytherapy source
Purpose: To present design aspects and acceptance tests performed for clinical implementation of electronic brachytherapytreatment of early stage rectal adenocarcinoma. A dosimetric comparison is made between the historically used Philips RT-50 unit and the newly developed Axxent® Model S700 electronic brachytherapysource manufactured by Xoft (iCad, Inc.). Methods: Two proctoscope cones were manufactured by ElectroSurgical Instruments (ESI). Two custom surface applicators were manufactured by Xoft and were designed to fit and interlock with the proctoscope cones from ESI. Dose rates, half value layers (HVL), and percentage depth dose (PDD) measurements were made with the Xoft system and compared to historical RT-50 data. A description of the patient treatment approach and exposure rates during the procedure is also provided. Results: The electronic brachytherapy system has a lower surfacedose rate than the RT-50. The dose rate to water on the surface from the Xoft system is approximately 2.1 Gy/min while the RT-50 is 10–12 Gy/min. However, treatment times with Xoft are still reasonable. The HVLs and PDDs between the two systems were comparable resulting in similar doses to the target and to regions beyond the target. The exposure rate levels around a patient treatment were acceptable. The standard uncertainty in the dose rate to water on the surface is approximately ±5.2%. Conclusions: The Philips RT-50 unit is an out-of-date radiotherapy machine that is no longer manufactured with limited replacement parts. The use of a custom-designed proctoscope and Xoft surface applicators allows delivery of a well-established treatment with the ease of a modern radiotherapy device. While the dose rate is lower with the use of Xoft, the treatment times are still reasonable. Additionally, personnel may stand farther away from the Xoft radiationsource, thus potentially reducing radiation exposure to the operator and other personnel.
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
Tu1760 Radiation Therapy for Locally Advanced Colon Cancer
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
Tu1760 Radiation Therapy for Locally Advanced Colon Cancer
- 9 March 2011
- Published by Wiley in Medical Physics
- Vol. 38 (4) , 1799-1805
Normal tissue dose conformality measures to guide radiotherapy fractionation decisions
To determine conditions under which hypofractionation could be favorable for a normal tissue--even if tumor [alpha/beta] exceeds the normal tissue's [alpha/beta]. The hypofractionation sufficiency condition (HSC) for an organ is defined as a dose conformality constraint such that, if satisfied, a family of tumor control probability isoeffective fractionation schemes will show decreasing normal tissue complication probability with decreasing number of fractions. In the extended equivalent uniform dose (EUD) model [obtained by replacing dose with linear quadratic (LQ) 2 Gy equivalent dose], the HSC for a normal organ is proven to be satisfied if a suitably weighted average of the relative dose [hypofractionation sufficiency index (HSI)] is less than the ratio of normal tissue to tumor [alpha/beta]. The HSI is determined solely by dose distribution and the normal tissue volume factor, "a." If the HSC is satisfied for every normal tissue of concern, then there is a therapeutic gain with hypofractionation. The corresponding multifractionation sufficiency condition (therapeutic gain with increasing number of fractions) and multifractionation sufficiency index (MSI) are also derived. A sample clinical case is presented. Within the context of the LQ/EUD models, conformality measures (HSI and MSI) can be used to inform fractionation decisions.
- 9 March 2011
- Published by Wiley in Medical Physics
- Vol. 38 (4) , 1799-1805
Normal tissue dose conformality measures to guide radiotherapy fractionation decisions
To determine conditions under which hypofractionation could be favorable for a normal tissue--even if tumor [alpha/beta] exceeds the normal tissue's [alpha/beta]. The hypofractionation sufficiency condition (HSC) for an organ is defined as a dose conformality constraint such that, if satisfied, a family of tumor control probability isoeffective fractionation schemes will show decreasing normal tissue complication probability with decreasing number of fractions. In the extended equivalent uniform dose (EUD) model [obtained by replacing dose with linear quadratic (LQ) 2 Gy equivalent dose], the HSC for a normal organ is proven to be satisfied if a suitably weighted average of the relative dose [hypofractionation sufficiency index (HSI)] is less than the ratio of normal tissue to tumor [alpha/beta]. The HSI is determined solely by dose distribution and the normal tissue volume factor, "a." If the HSC is satisfied for every normal tissue of concern, then there is a therapeutic gain with hypofractionation. The corresponding multifractionation sufficiency condition (therapeutic gain with increasing number of fractions) and multifractionation sufficiency index (MSI) are also derived. A sample clinical case is presented. Within the context of the LQ/EUD models, conformality measures (HSI and MSI) can be used to inform fractionation decisions.
- 1 October 2009
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 75 (2) , 428-435
Radiotherapy for Epidermoid Carcinoma of the Anus: Thirty Years' Experience
- 1 October 2009
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 75 (2) , 428-435
Radiotherapy for Epidermoid Carcinoma of the Anus: Thirty Years' Experience
- Top Cited Papers
- 1 July 2009
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 74 (3) , 824-830
Elective Clinical Target Volumes for Conformal Therapy in Anorectal Cancer: A Radiation Therapy Oncology Group Consensus Panel Contouring Atlas
- 1 July 2009
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 74 (3) , 824-830
Top Cited PapersElective Clinical Target Volumes for Conformal Therapy in Anorectal Cancer: A Radiation Therapy Oncology Group Consensus Panel Contouring Atlas
- 1 November 2007
- Published by Elsevier in Clinical Oncology
- Vol. 19 (9) , 682-686
Conservative Alternatives to Extirpative Surgery for Rectal Cancer
- 1 November 2007
- Published by Elsevier in Clinical Oncology
- Vol. 19 (9) , 682-686
Conservative Alternatives to Extirpative Surgery for Rectal Cancer